Awad MM, Katayama R, McTigue M, Liu W, Deng Y-L, Brooun A, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368:2395–401.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.
Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer treatment reports. 1983;67:923–31.
Coldman AJ, Goldie JH. A stochastic model for the origin and treatment of tumors containing drug resistant cells. Bull Math Biol. 1986;48:279–92.
Carman MD, Schornagel JH, Rivest RS, Srimatkandada S, Portlock CS, Duffy T, et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol. 1984;2:16–20.
Trent JM, Buick RN, Olson S, Horns RC, Schimke RT. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol. 1984;2:8–15.
Wang TL, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A. 2004;101:3089–94.
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117:2562–9.
Aktipis CA, Kwan VSY, Johnson KA, Neuberg SL, Maley CC. Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research. PLoS ONE. 2011;6:e26100.
Postmus PE, Berendsen HH, van Zandwijk N, Splinter TAW, Burghouts JTM, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. European Journal of Cancer and Clinical Oncology. 1987;23:1409–11.
Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, et al. Small-cell carcinoma of lung: Reinduction therapy after late relapse. Ann Intern Med. 1983;98:472–4.
Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol. 2013;10:571–87.
van Aerts RMM, Kolkman M, Kievit W, Gevers TJG, Nevens F, Drenth JPH. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues. Ther Adv Gastroenterol. 2018;11.
Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561–74.
Holmes D. Ovarian cancer: beyond resistance. Nature. 2015;527:S217–S217.
Niveditha D, Mukherjee S, Majumder S, Chowdhury R, Chowdhury S. A global transcriptomic pipeline decoding core network of genes involved in stages leading to acquisition of drug-resistance to cisplatin in osteosarcoma cells. Bioinformatics. 2019;35:1701–11.
Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.
Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
D.D. M, H.H. L. Osteosarcoma. Cancer Treatment and Research. 2014;162:65–92.
Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K. Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 2009;14:108–23.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods (San Diego, Calif). 2001;25:402–8.
Ray U, Roy SS, Chowdhury SR. Lysophosphatidic acid promotes epithelial to Mesenchymal transition in ovarian Cancer cells by repressing SIRT1. Cell Physiol Biochem. 2017;41:795–805.
Mukherjee S, Dash S, Lohitesh K, Chowdhury R. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. PLoS One. 2017;12:e0179203.
Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P. Peat G, et al. Transcription factor activities enhance markers of drug sensitivity in cancer. Cancer Res. 2018;78:769–80.
Gonda TJ, Ramsay RG. Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer. 2015;15:686–94.
Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet. 2009;10:252–63.
Yang Y, Zhang F, Ding R, Skrip L, Wang Y, Lei H, et al. ADIPOQ gene polymorphisms and cancer risk: a meta-analysis. Cytokine. 2013;61:565–71.
Gagnon V, Mathieu I, Sexton É, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004;94:785–95.
Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL, et al. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci. 2011;102:1822–8.
Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, et al. ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy. 2017;13:1386–403.
Sun L, Sui L, Cong X, Ma K, Ma X, Huang Y, et al. Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort. Cancer Genetics. 2014;207:291–8.
Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.
Wang T, Donahoe PK. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Frontiers in bioscience : a journal and virtual library. 2004;9:619–31.
Cheung LWT, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discovery. 2011;1:170–85.
Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85 of phosphoinositide 3-kinase function through the catalytic subunit p110. Proc Natl Acad Sci. 2010;107:15547–52.
Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21–41.
Deng L, Zhu X, Sun Y, Wang J, Zhong X, Li J, et al. Prevalence and prognostic role of PIK3CA/AKT1 mutations in Chinese breast cancer patients. Cancer Res Treat. 2019;51:128–40.
Yamato A, Soda M, Ueno T, Kojima S, Sonehara K, Kawazu M, et al. Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential. Cancer Sci. 2015;106:1137–42.
Zeng R, Huang J, Zhong M, Li L, Yang G, Liu L, et al. Multiple roles of WNT5A in breast Cancer. Med Sci Monit. 2016;22:5058–67.
Wee S, Wiederschain D, Maira S-M, Loo A, Miller C, de Beaumont R, et al. PTEN-deficient cancers depend on PIK3CB. Proc Nat Acad Sci. 2008;105:13057–62.
Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ. Functional characterization of a novel somatic oncogenic mutation of PIK3CB. Signal Transduction and Targeted Therapy. 2017;2:17063.
Rigueur D, Brugger S, Anbarchian T, Kim JK, Lee Y, Lyons KM. The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development. J Bone Miner Res. 2015;30:733–41.
Yasuda K, Hirohashi Y, Kuroda T, Takaya A, Kubo T, Kanaseki T, et al. MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation. Biochem Biophys Res Commun. 2016;472:643–7.
Tan FLS, Ooi A, Huang D, Wong JC, Qian CN, Chao C, et al. p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer. 2010;126:2353–61.
Gao AC, Lou W, Isaacs JT. Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene. Clin Cancer Res. 2000;6:493–7.
Gao AC, Lou W, Isaacs JT. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity. Cancer Res. 1998;58:1391–4.
Wang M, Tang L, Liu D, Ying QL, Ye S. The transcription factor Gbx2 induces expression of Kruppel-like factor 4 to maintain and induce naïve pluripotency of embryonic stem cells. J Biol Chem. 2017;292:17121–8.
Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–81.
Manda G, Isvoranu G, Comanescu MV, Manea A, Debelec Butuner B, Korkmaz KS. The redox biology network in cancer pathophysiology and therapeutics. Redox Biol. 2015;5:347–57.
Bellmunt J, Albiol S, Albanell J. Intermittent chemotherapy in metastatic androgen- independent prostate cancer. BJU Int. 2007;100:490–2.
Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2004;91:1425–27.
Madan RA, Pal SK, Sarto O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res. 2011;17:3892–902.
Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, et al. Drug holiday in metastatic renal-cell carcinoma patients treated with vascular endothelial growth factor receptor inhibitors. Clinical Genitourinary Cancer. 2018;16:e663–7.
Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, et al. Exploiting drug addiction mechanisms to select against mapki-resistant melanoma. Cancer Discovery. 2018;8:74–93.
Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in Cancer cell subpopulations. Cell. 2010;141:69–80.